Loading...

SANA SANA BIOTECHNOLOGY INC Expansion Plans 8-K Filing

SN B

SN

SANA BIOTECHNOLOGY INC

(SANA)

2025 8-K

Show Summary

Summary

Product Expansion

Equity Offerings

Financial Results

Corporate Presentation

Financial Results

Management Changes

Management Change

Earnings Reports

Annual Meeting Results

Financial Results Announcement

Resignation of Executive

Financial Results Announcement

Public Offering

Financial Update

Conference Presentation

Financial Results Announcement

Portfolio Update and Workfo...

Regulation FD Disclosure

Termination of Lease Agreement

Financial Results Announcement

Annual Meeting Results

Presentation at Conference

Earnings Reports

Resignation of Executive

Management Changes

Financial Results Announcement

FDA Clearance for First-in-...

FDA Clearance for First-in-...

Regulation FD Disclosure

External Links:

On June 23, 2025, Sana Biotechnology, Inc. reported promising six-month results from a first-in-human study of its UP421 therapy for type 1 diabetes, showing it was effective without the need for immunosuppression.

AI Assistant

SANA BIOTECHNOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.